The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety and clinical activity of adenosine A2a receptor (A2aR) antagonist, CPI-444, in anti-PD1/PDL1 treatment-refractory renal cell (RCC) and non-small cell lung cancer (NSCLC) patients.
 
Patrick M. Forde
Research Funding - AstraZeneca; Bristol-Myers Squibb; Kyowa Hakko Kirin; Novartis
 
John D. Powderly
Employment - BioCytics; Carolina BioOncology Institute
Leadership - BioCytics; Carolina BioOncology Institute
Stock and Other Ownership Interests - BioCytics; Bluebird Bio; Carolina BioOncology Institute; Juno Therapeutics; Kite, a Gilead company; Lion Biotechnologies; ZIOPHARM Oncology
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Curis; Genentech/Roche; TopAlliance BioSciences Inc
Speakers' Bureau - Bristol-Myers Squibb; Dendreon; Genentech/Roche; Merck
Research Funding - Abbvie; AstraZeneca/MedImmune; Bristol-Myers Squibb; Corvus Pharmaceuticals; Curis; EMD Serono; Genentech/Roche; Incyte; Lilly/ImClone; Macrogenics; Seagen; Top Alliance BioScience
Patents, Royalties, Other Intellectual Property - BioCytics is developing intellectual property for cellular immunotherapy
 
Jonathan Wade Goldman
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Clovis Oncology; Genentech/Roche; Lilly; Trovagene; Vortex Biosciences
Research Funding - Abbvie; Array BioPharma; Astellas Pharma; Astex Pharmaceuticals; AstraZeneca/MedImmune; Bristol-Myers Squibb; Celgene; Clovis Oncology; Corvus Pharmaceuticals; Genentech/Roche; Lilly; Threshold Pharmaceuticals
 
John J. Nemunaitis
Employment - Gradalis
Leadership - Gradalis
Stock and Other Ownership Interests - Gradalis
Honoraria - Amgen; AstraZeneca
Consulting or Advisory Role - Amgen; AstraZeneca
Speakers' Bureau - Amgen; AstraZeneca
Patents, Royalties, Other Intellectual Property - Gradalis
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Baxalta; Takeda
 
Jason John Luke
Honoraria - Intellisphere, LLC
Consulting or Advisory Role - Amgen; Array BioPharma; AstraZeneca/MedImmune; Benevir; Bristol-Myers Squibb; Checkmate Pharmaceuticals; EMD Serono; Merck; Novartis
Research Funding - Abbvie; Boston Biomedical; Bristol-Myers Squibb; Celldex; Corvus Pharmaceuticals; Delcath Systems; Five Prime Therapeutics; Genentech/Roche; Immunocore; Incyte; MedImmune; Merck; Pharmacyclics
Travel, Accommodations, Expenses - Amgen; Array BioPharma; AstraZeneca/MedImmune; Bristol-Myers Squibb
 
Matthew David Hellmann
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Genentech; Janssen; Merck; Novartis
Research Funding - Bristol-Myers Squibb; Genentech/Roche
 
Shivaani Kummar
Consulting or Advisory Role - Corvus Pharmaceuticals; MedTree (I)
Research Funding - Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Dynavax Technologies (Inst); Loxo (Inst); Pfizer (Inst)
 
Robert Charles Doebele
Honoraria - AstraZeneca; Clovis Oncology; Loxo; OxOnc; Pfizer
Consulting or Advisory Role - Array BioPharma; Lilly; Loxo; OxOnc; Pfizer; Pfizer
Research Funding - Abbott Molecular; Loxo; Mirati Therapeutics
Patents, Royalties, Other Intellectual Property - Licensing Fees for Biologic Material from Ariad (Inst); Licensing Fees for Biologic Material from Blueprint Medicines (Inst); Licensing Fees for Biologic Material from Chugai (Inst); Licensing Fees for Biologic Materials from GVKbio; Licensing Fees for Biologic Materials from Loxo Oncology (Inst); Licensing Fees from Abbott Molecular for Patent PCT/US2013/057495
Travel, Accommodations, Expenses - Ignyta
 
Daruka Mahadevan
Consulting or Advisory Role - Abbvie; Alexion Pharmaceuticals
 
Shirish M. Gadgeel
Consulting or Advisory Role - ARIAD; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech/Roche; Novartis; Pfizer
Speakers' Bureau - AstraZeneca; Genentech/Roche
Research Funding - ACEA Biosciences (Inst); Acerta Pharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Five Prime Therapeutics (Inst); Genentech/Roche (Inst); Halozyme (Inst); Incyte (Inst); Janssen Oncology (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); OncoMed (Inst); Pfizer (Inst)
 
Brett Gordon Maxwell Hughes
No Relationships to Disclose
 
Ben Markman
No Relationships to Disclose
 
Matthew John Riese
Consulting or Advisory Role - Abbvie; Exelixis; Incyte
Research Funding - Bristol-Myers Squibb; Incyte
 
Joshua Brody
Consulting or Advisory Role - Celldex; Merck
Research Funding - Acerta Pharma (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); Gilead Sciences (Inst); Merck (Inst)
 
Leisha A. Emens
Employment - FDA; Johns Hopkins University School of Medicine
Leadership - Society for Immunotherapy of Cancer
Stock and Other Ownership Interests - Molecuvax
Honoraria - American Society for Radiation Oncology; ASCO; Society for Immunotherapy of Cancer
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Celgene; etheRNA; Molecuvax; Peregrine Pharmaceuticals; Syndax; Vaccinex
Research Funding - Aduro Biotech; AstraZeneca; Corvus Pharmaceuticals; EMD Serono; Genentech; Maxcyte; Merck; Roche
Other Relationship - Aduro Biotech
 
Ian McCaffery
Employment - Corvus Pharmaceuticals; Genentech
Stock and Other Ownership Interests - Corvus Pharmaceuticals; Roche
Patents, Royalties, Other Intellectual Property - Genentech
 
Richard Alan Miller
Employment - Corvus Pharmaceuticals; Genentech/Roche (I)
Leadership - Corvus Pharmaceuticals; Genentech/Roche (I)
Stock and Other Ownership Interests - Corvus Pharmaceuticals; Genentech/Roche (I)
 
Ginna Laport
Employment - Corvus Pharmaceuticals
Stock and Other Ownership Interests - Corvus Pharmaceuticals